003850.KS
Boryung Corporation
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 8,900.00
+0.45%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1060.3B | 1017.4B | 1017.1B | 859.6B | 760.5B |
| Cost of Revenue | 690.1B | 664.9B | 653.7B | 506.2B | 453.3B |
| Gross Profit | 365.3B | 352.5B | 363.4B | 353.4B | 307.2B |
| Operating Expenses | |||||
| R&D Expense | 47.7B | 65.1B | 51.5B | 47.3B | 41.7B |
| SG&A Expense | 129.8B | 99.6B | 99.1B | 92.1B | 92.0B |
| General & Admin Expense | 17.9B | 20.7B | 21.3B | 19.2B | 17.9B |
| Selling & Marketing Expense | 78.1B | 78.8B | 77.7B | 72.8B | 74.2B |
| Other Expenses | 134.3B | 122.8B | 142.3B | 145.8B | 116.9B |
| Total Operating Expenses | 292.5B | 287.4B | 292.9B | 285.2B | 250.6B |
| Cost and Expenses | 987.6B | 950.5B | 946.6B | 791.9B | 703.9B |
| Operating Income (EBIT) | 72.7B | 65.1B | 70.5B | 68.3B | 56.6B |
| Non-Operating | |||||
| Interest Income | 12.4B | 8.6B | 6.0B | 871.8M | 4.5B |
| Interest Expense | 13.2B | 11.6B | 9.0B | 9.5B | 6.1B |
| Net Interest Income | (841.2M) | (3.0B) | (3.0B) | (8.7B) | (1.6B) |
| Other Non-Op Income/Expense | 75.0B | 4.8B | (7.5B) | (12.0B) | 2.3B |
| Non-Operating Income (excl Interest) | (40.8B) | (16.4B) | (1.5B) | 2.4B | (12.6B) |
| EBT (Pre-Tax Income) | 147.7B | 69.8B | 63.0B | 56.3B | 58.9B |
| Income Tax Expense | 27.1B | 5.5B | (6.7B) | 16.1B | 16.9B |
| Bottom Line | |||||
| Net Income | 120.6B | 64.3B | 69.6B | 40.2B | 41.9B |
| Earnings from Cont. Ops | 120.6B | 64.3B | 69.6B | 40.2B | 41.9B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 120.6B | 64.3B | 69.6B | 40.2B | 41.9B |
| Per Share | |||||
| Basic EPS | ₩1,436 | ₩766 | ₩1,020 | ₩610 | ₩636 |
| Diluted EPS | ₩1,435 | ₩766 | ₩1,016 | ₩610 | ₩634 |
| Revenue Per Share | ₩12,360 | ₩12,120 | ₩14,894 | ₩13,051 | ₩11,543 |
| Shares | |||||
| Basic Shares Outstanding | 85.8M | 83.9M | 68.3M | 65.9M | 65.9M |
| Diluted Shares Outstanding | 85.8M | 83.9M | 68.5M | 65.9M | 66.1M |
| Profitability Metrics | |||||
| EBITDA | 137.2B | 108.6B | 114.8B | 110.2B | 105.7B |
| D&A | 47.4B | 43.5B | 42.8B | 44.4B | 36.6B |
| EBIT | 90.0B | 65.1B | 72.0B | 65.9B | 69.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026